How Molecular Topology Can Help in Amyotrophic Lateral Sclerosis (ALS) Drug Development: A Revolutionary Paradigm for a Merciless Disease
Open Access
- 14 January 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (1) , 94
Abstract
Even if amyotrophic lateral sclerosis is still considered an orphan disease to date, its prevalence among the population is growing fast. Despite the efforts made by researchers and pharmaceutical companies, the cryptic information related to the biological and physiological onset mechanisms, as well as the complexity in identifying specific pharmacological targets, make it almost impossible to find effective treatments. Furthermore, because of complex ethical and economic aspects, it is usually hard to find all the necessary resources when searching for drugs for new orphan diseases. In this context, computational methods, based either on receptors or ligands, share the capability to improve the success rate when searching and selecting potential candidates for further experimentation and, consequently, reduce the number of resources and time taken when delivering a new drug to the market. In the present work, a computational strategy based on Molecular Topology, a mathematical paradigm capable of relating the chemical structure of a molecule to a specific biological or pharmacological property by means of numbers, is presented. The result was the creation of a reliable and accessible tool to help during the early in silico stages in the identification and repositioning of potential hits for ALS treatment, which can also apply to other orphan diseases. Considering that further computational and experimental results will be required for the final identification of viable hits, three linear discriminant equations combined with molecular docking simulations on specific proteins involved in ALS are reported, along with virtual screening of the Drugbank database as a practical example. In this particular case, as reported, a clinical trial has been already started for one of the drugs proposed in the present study.Keywords
This publication has 39 references indexed in Scilit:
- The crystal structure of TDP-43 RRM1-DNA complex reveals the specific recognition for UG- and TG-rich nucleic acidsNucleic Acids Research, 2014
- Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43Nature Structural & Molecular Biology, 2013
- On the Development and Validation of QSAR Models2012
- Equivalence of improvement in area under ROC curve and linear discriminant analysis coefficient under assumption of normalityStatistics in Medicine, 2011
- ChemSpider: An Online Chemical Information ResourceJournal of Chemical Education, 2010
- TDP-43 Proteinopathies: Neurodegenerative Protein Misfolding Diseases without AmyloidosisNeurosignals, 2007
- Cross-validation as the objective function for variable-selection techniquesTrAC Trends in Analytical Chemistry, 2003
- Assessing Model Fit by Cross-ValidationJournal of Chemical Information and Computer Sciences, 2003
- New drugs and combinations in the palliative treatment of colon and rectal cancerEuropean Journal of Surgical Oncology, 2001
- Pharmacological distribution diagrams: A tool for de novo drug designJournal of Molecular Graphics, 1996